Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Purdue Pharma boosts opioid lawsuits settlement offer to $4.28 billion

By Brian Buntz | March 16, 2021

Purdue PharmaPurdue Pharma has proposed paying an additional approximately $500 million in cash to settle hundreds of thousands of opioid lawsuits.

As part of a proposed bankruptcy settlement, the payments would be spaced out over the next decade. The Sackler family that owns the company has earlier agreed to pay an additional $4.2 billion to settle a range of civil claims. The total settlement amount is roughly $4.28 billion.

The latest proposal has immediately faced opposition from two dozen state attorneys general.

The proposal, which would also strip the Sackler family of Purdue Pharma ownership, would need approval from a federal bankruptcy court in White Plains, N.Y.

But the agreement would allow the family to continue managing offshore subsidiaries for at least seven years.

Purdue family admitted in 2007 and 2020 that it illegally marked opioids such as OxyContin in plea deals with the Justice Department.

The latest proposal would turn Purdue Pharma into a new company with an independent board.

The company would continue selling OxyContin and other drugs, but the company would prioritize medicines that treat overdoses and opioid addiction.

“With drug overdoses still at record levels, it is past time to put Purdue’s assets to work addressing the crisis,” said Purdue Pharma president Steve Miller in prepared remarks. “We are confident this plan achieves that critical goal.”

Companies ranging from McKinsey to Johnson & Johnson and distributors like McKesson have also been entangled in opioid settlements.

 

Tell Us What You Think! Cancel reply

Related Articles Read More >

Johnson & Johnson
Fauci: J&J vaccination could resume shortly
Pfizer BioNTech
EU secures additional 100 million Pfizer-BioNTech vaccine doses
BioDelivery Sciences
President of BioDelivery Sciences on the future of chronic pain management
Catalent Biologics Madison Facility
Catalent expands biologics manufacturing facility in Wisconsin

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards